Cracking the Code: Syner-G’s Blueprint for Success with Pharmaceutical Stability Studies

Every year, the FDA handles a staggering 1,500 Investigational New Drug (IND) applications, a critical step in bringing pharmaceutical innovations to market. The IND review process is pivotal, ensuring the safety of study subjects and the integrity of clinical trials. To successfully navigate this complex landscape, understanding the FDA’s priorities, common stumbling blocks, and the benefits of pre-IND meetings is essential.